Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases. A systematic review of literature

Francesco Londero; William Grossi; Angelo Morelli; Orlando Parise; Gianluca Masullo; Cecilia Tetta; Ugolino Livi; Jos G Maessen; Sandro Gelsomino

doi:10.2144/fsoa-2019-0120

Surgery versus stereotactic radiotherapy for treatment of pulmonary metastases. A systematic review of literature

Future Sci OA. 2020 Apr 15;6(5):FSO471. doi: 10.2144/fsoa-2019-0120.

Authors

Francesco Londero¹, William Grossi¹, Angelo Morelli¹, Orlando Parise², Gianluca Masullo¹, Cecilia Tetta³, Ugolino Livi¹, Jos G Maessen², Sandro Gelsomino²

Affiliations

¹ Department of Cardiothoracic Surgery, S. Maria della Misericordia University Hospital, Udine, Italy.
² Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands.
³ Radiology Department, Rizzoli Institute, Bologna, Italy.

Abstract

It is not clear as to which is the best treatment among surgery and stereotactic radiotherapy (SBRT) for lung oligometastases. A systematic review of literature with a priori selection criteria was conducted on articles on the treatment of pulmonary metastases with surgery or SBRT. Only original articles with a population of patients of more than 50 were selected. After final selection, 61 articles on surgical treatment and 18 on SBRT were included. No difference was encountered in short-term survival between pulmonary metastasectomy and SBRT. In the long-term surgery seems to guarantee better survival rates. Mortality and morbidity after treatment are 0-4.7% and 0-23% for surgery, and 0-2% and 4-31% for SBRT. Surgical metastasectomy remains the treatment of choice for pulmonary oligometastases.

Keywords: lung; oligometastases; oligorecurrence; radiotherapy; surgery.

Publication types

Review